Vontobel Holding Ltd. Buys 382,161 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Vontobel Holding Ltd. boosted its holdings in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 125.8% in the fourth quarter, Holdings Channel reports. The firm owned 685,985 shares of the company’s stock after purchasing an additional 382,161 shares during the quarter. Vontobel Holding Ltd.’s holdings in PMV Pharmaceuticals were worth $2,127,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its stake in PMV Pharmaceuticals by 94.7% during the second quarter. Royal Bank of Canada now owns 4,024 shares of the company’s stock worth $25,000 after purchasing an additional 1,957 shares during the period. Quantbot Technologies LP bought a new position in PMV Pharmaceuticals during the second quarter worth about $26,000. US Bancorp DE lifted its stake in PMV Pharmaceuticals by 2,588.0% during the first quarter. US Bancorp DE now owns 2,016 shares of the company’s stock worth $42,000 after purchasing an additional 1,941 shares during the period. SG Americas Securities LLC bought a new position in PMV Pharmaceuticals during the fourth quarter worth about $65,000. Finally, State Board of Administration of Florida Retirement System bought a new position in PMV Pharmaceuticals during the second quarter worth about $69,000. Institutional investors own 90.20% of the company’s stock.

PMV Pharmaceuticals Stock Up 0.6 %

NASDAQ PMVP opened at $1.62 on Friday. The company has a 50 day moving average of $1.68 and a 200-day moving average of $2.20. PMV Pharmaceuticals, Inc. has a 1-year low of $1.18 and a 1-year high of $9.72.

PMV Pharmaceuticals (NASDAQ:PMVP) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.08. Sell-side analysts expect that PMV Pharmaceuticals, Inc. will post -1.44 earnings per share for the current year.

Analysts Set New Price Targets

PMVP has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of PMV Pharmaceuticals in a report on Thursday, March 7th. LADENBURG THALM/SH SH initiated coverage on shares of PMV Pharmaceuticals in a report on Wednesday, December 27th. They set a “buy” rating and a $7.00 price objective for the company. Finally, Jefferies Financial Group initiated coverage on shares of PMV Pharmaceuticals in a report on Friday, April 12th. They set a “buy” rating and a $5.00 price objective for the company.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.